Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

The effects of atorvastatin on oxidative stress in L-NAME-treated rats.

Sozer V, Uzun H, Gelisgen R, Kaya M, Kalayci R, Tabak O, Arican N, Konukoglu D.

Scand J Clin Lab Invest. 2013 Oct;73(7):591-7. doi: 10.3109/00365513.2013.828241. Epub 2013 Sep 12.

PMID:
24024670
2.

Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation.

Sezer ED, Sozmen EY, Nart D, Onat T.

Vasc Health Risk Manag. 2011;7:333-43. doi: 10.2147/VHRM.S17781. Epub 2011 Jun 1.

3.

Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis.

Lecian D, Demova H, Lodererova A, Zdychova J, Kluckova H, Teplan V, Voska L, Komers R.

Kidney Blood Press Res. 2006;29(3):135-43. Epub 2006 Aug 7.

4.

Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status.

Nagila A, Permpongpaiboon T, Tantrarongroj S, Porapakkham P, Chinwattana K, Deakin S, Porntadavity S.

Pharmacol Rep. 2009 Sep-Oct;61(5):892-8.

5.

Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity.

Harangi M, Mirdamadi HZ, Seres I, Sztanek F, Molnár M, Kassai A, Derdák Z, Illyés L, Paragh G.

Transl Res. 2009 Apr;153(4):190-8. doi: 10.1016/j.trsl.2009.01.007. Epub 2009 Feb 14.

PMID:
19304278
6.

Atorvastatin ameliorates arsenic-induced hypertension and enhancement of vascular redox signaling in rats.

Sarath TS, Waghe P, Gupta P, Choudhury S, Kannan K, Pillai AH, Harikumar SK, Mishra SK, Sarkar SN.

Toxicol Appl Pharmacol. 2014 Nov 1;280(3):443-54. doi: 10.1016/j.taap.2014.08.032. Epub 2014 Sep 11.

PMID:
25218292
7.

Physical training prevents oxidative stress in L-NAME-induced hypertension rats.

Cardoso AM, Martins CC, Fiorin Fda S, Schmatz R, Abdalla FH, Gutierres J, Zanini D, Fiorenza AM, Stefanello N, Serres JD, Carvalho F, Castro VP, Mazzanti CM, Royes LF, Belló-Klein A, Goularte JF, Morsch VM, Bagatini MD, Schetinger MR.

Cell Biochem Funct. 2013 Mar;31(2):136-51. doi: 10.1002/cbf.2868. Epub 2012 Sep 7.

PMID:
22961602
8.

Effects of atorvastatin on blood-brain barrier permeability during L-NAME hypertension followed by angiotensin-II in rats.

Kalayci R, Kaya M, Elmas I, Arican N, Ahishali B, Uzun H, Bilgic B, Kucuk M, Kudat H.

Brain Res. 2005 May 3;1042(2):184-93.

PMID:
15854590
9.
10.

Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine.

Bolayirli IM, Aslan M, Balci H, Altug T, Hacibekiroglu M, Seven A.

Life Sci. 2007 Jun 20;81(2):121-7. Epub 2007 May 6.

PMID:
17532348
11.
12.
13.

Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.

Abdin AA, Hassanien MA, Ibrahim EA, El-Noeman Sel-D.

J Diabetes Complications. 2010 Sep-Oct;24(5):325-33. doi: 10.1016/j.jdiacomp.2009.04.001. Epub 2009 Jun 23.

PMID:
19553142
14.

Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.

Sardo MA, Campo S, Bonaiuto M, Bonaiuto A, Saitta C, Trimarchi G, Castaldo M, Bitto A, Cinquegrani M, Saitta A.

Curr Med Res Opin. 2005 May;21(5):777-84.

PMID:
15969877
15.

[The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia].

Broncel M, Koter-Michalak M, Chojnowska-Jezierska J.

Przegl Lek. 2006;63(9):738-42. Polish.

PMID:
17479860
16.

Physicochemical modifications induced by statins therapy on human erythrocytes membranes.

Broncel M, Bała A, Koter-Michalak M, Duchnowicz P, Wojsznis W, Chojnowska-Jezierska J.

Wiad Lek. 2007;60(7-8):321-8.

PMID:
18175550
17.
18.

Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks.

Sumegová K, Blazícek P, Waczulíková I, Zitnanová I, Duracková Z.

Acta Biochim Pol. 2006;53(4):783-7. Epub 2006 Nov 14.

19.

Counter-regulation by atorvastatin of gene modulations induced by L-NAME hypertension is associated with vascular protection.

Nadaud S, Dupuis M, Brocheriou I, Haloui M, Louedec L, Capron F, Michel JB, Soubrier F.

Vascul Pharmacol. 2009 Oct;51(4):253-61. doi: 10.1016/j.vph.2009.06.011. Epub 2009 Jul 5.

PMID:
19586617
20.

Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.

Mazza F, Stefanutti C, Di Giacomo S, Vivenzio A, Fraone N, Mazzarella B, Bucci A.

Am J Cardiovasc Drugs. 2008;8(4):265-70.

PMID:
18690760

Supplemental Content

Support Center